These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 26880588)
1. Comparison of in vitro antileukemic activity of obatoclax and ABT-737. Opydo-Chanek M; Mazur L Tumour Biol; 2016 Aug; 37(8):10839-49. PubMed ID: 26880588 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169 [TBL] [Abstract][Full Text] [Related]
4. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. Opydo-Chanek M; Rak A; Cierniak A; Mazur L Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708 [TBL] [Abstract][Full Text] [Related]
5. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. Wroblewski D; Jiang CC; Croft A; Farrelly ML; Zhang XD; Hersey P PLoS One; 2013; 8(12):e84073. PubMed ID: 24367627 [TBL] [Abstract][Full Text] [Related]
6. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015 [TBL] [Abstract][Full Text] [Related]
7. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671 [TBL] [Abstract][Full Text] [Related]
8. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
9. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. Pandey MK; Gowda K; Doi K; Sharma AK; Wang HG; Amin S PLoS One; 2013; 8(11):e78570. PubMed ID: 24223823 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis. Harnett CC; Abusneina A; Clément J; Gauthier ER Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811 [TBL] [Abstract][Full Text] [Related]
12. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. Abed MN; Abdullah MI; Richardson A J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533 [TBL] [Abstract][Full Text] [Related]
13. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615 [TBL] [Abstract][Full Text] [Related]
14. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594 [TBL] [Abstract][Full Text] [Related]
15. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells. Kim LH; Shin JA; Jang B; Yang IH; Won DH; Jeong JH; Chung TH; Cho NP; Cho SD Arch Oral Biol; 2017 Jan; 73():1-6. PubMed ID: 27632413 [TBL] [Abstract][Full Text] [Related]
18. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins. Renault TT; Elkholi R; Bharti A; Chipuk JE J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574 [TBL] [Abstract][Full Text] [Related]
19. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525 [TBL] [Abstract][Full Text] [Related]
20. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Huang S; Sinicrope FA Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]